Qing Yi, MD, PhD

Medicine & Life Sciences

1. Multiple Myeloma 100%
2. T-Lymphocytes 55%
3. Dendritic Cells 37%
4. Immunotherapy 36%
5. Neoplasms 32%
6. Mantle-Cell Lymphoma 27%
7. Myasthenia Gravis 27%
8. Immunity 17%
9. Interleukin-9 17%
10. Apoptosis 17%
11. B-Lymphocytes 16%
12. Bortezomib 15%
13. dectin 1 14%
14. p38 Mitogen-Activated Protein Kinases 13%
15. Osteoclasts 12%
16. In Vitro Techniques 12%
17. Cholinergic Receptors 12%
18. Macrophages 12%
19. Growth 11%
20. Neoplasm Antigens 11%
21. Monoclonal Antibodies 11%
22. Vaccines 11%
23. Interleukin-33 10%
24. Monoclonal Gammopathy of Undetermined Significance 10%
25. Paraproteinemias 10%
26. Cytotoxic T-Lymphocytes 9%
27. HLA-A*02:01 antigen 9%
28. Lenalidomide 9%
29. Myeloma Proteins 9%
30. Bone Marrow 9%
31. Antibodies 8%
32. Interleukin-2 8%
33. Therapeutics 8%
34. Helper-Inducer T-Lymphocytes 8%
35. Interferons 8%
36. Chimeric Antigen Receptors 8%
37. Blood Cells 8%
38. T-Lymphocyte Subsets 8%
39. Peptides 8%
40. Major Histocompatibility Complex 8%
41. Cell Survival 8%
42. Cytokines 7%
43. Monocytes 7%
44. Hepatocellular Carcinoma 7%
45. Interleukin-6 7%
46. Proteins 7%
47. Drug Therapy 7%
48. Tumor Microenvironment 7%
49. Proteasome Inhibitors 7%
50. Immune System 7%